This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Biotech ETF (BBC) Touches a New 52-Week High
by Sanghamitra Saha
The BBC ETF hit a 52-week high as strong trial updates and biotech momentum raise hopes for more gains ahead.
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
by Sanghamitra Saha
Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.
Biotech ETF (BBC) Touches Fresh 52-Week High
by Zacks Equity Research
Biotech ETF BBC hits a 52-week high, likely fueled by strong clinical trial results and rising M&A activity, and renewed risk-on sentiment.
Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?
by Sanghamitra Saha
Q4's top ETF winners -- silver, biotech and lithium -- outpaced markets. Can SIVR, SLV, BBC and LITP extend gains into 2026?
Biotech ETF (BBC) Hits New 52-Week High
by Sanghamitra Saha
Biotech ETF BBC hits a 52-week high amid renewed sector momentum, Fed rate cuts and AI-driven healthcare gains, hinting at more near-term upside.
The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI
by Zacks Equity Research
LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.
Best-Performing ETFs of Last Week: Healthcare Rules
by Sanghamitra Saha
Healthcare and biotech led last week's winners, with EPHE, BBC, HELX, XHS and SURI topping ETF gains as markets slid on AI worries and Fed uncertainty.
Best-Performing ETFs of Last Week
by Sanghamitra Saha
Top ETFs that soared last week despite market swings included shipping (BWET), lithium miners (LITP), crypto bear (REKT), biotech (BBC) and rare earths (REMX).
Biotech ETFs Hovering Around a 52-Week: Here's Why
by Sanghamitra Saha
Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?
Biotech ETF (BBC) Hits New 52-Week High
by Sanghamitra Saha
Biotech ETF BBC just hit a 52-week high on regulatory tailwinds, Fed rate-cut hopes, and cheaper valuations.